Literature DB >> 17606689

In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.

W T M Jansen1, A Verel, J Verhoef, D Milatovic.   

Abstract

The in vitro activity of telavancin was tested against 620 gram-positive isolates. For staphylococci, MICs at which 50 and 90% of isolates were inhibited (MIC(50) and MIC(90)) were both 0.25 microg/ml, irrespective of methicillin resistance. MIC(50) and MIC(90) were 0.25 and 0.5 microg/ml for vancomycin-susceptible enterococci and 1 and 2 microg/ml for vancomycin-resistant enterococci, respectively. Streptococcus pneumoniae, group A and B beta-hemolytic streptococci, and viridans streptococci were inhibited by < or =0.12 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17606689      PMCID： PMC2043219          DOI： 10.1128/AAC.00100-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.

Authors:  J P Shaw; J Seroogy; K Kaniga; D L Higgins; M Kitt; S Barriere
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 3.  Recent developments in glycopeptide antibacterials.

Authors:  John F Barrett
Journal:  Curr Opin Investig Drugs       Date:  2005-08

4.  Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.

Authors:  Kimberly D Leuthner; Chrissy M Cheung; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2006-06-20       Impact factor: 5.790

5.  Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.

Authors:  Martin E Stryjewski; William D O'Riordan; William K Lau; Francis D Pien; Lala M Dunbar; Marc Vallee; Vance G Fowler; Vivian H Chu; Elizabeth Spencer; Steven L Barriere; Michael M Kitt; Christopher H Cabell; G Ralph Corey
Journal:  Clin Infect Dis       Date:  2005-04-28       Impact factor: 9.079

Review 6.  Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

Authors:  Françoise Van Bambeke
Journal:  Curr Opin Pharmacol       Date:  2004-10       Impact factor: 5.547

7.  In vitro activity of TD-6424 against Staphylococcus aureus.

Authors:  John L Pace; Kevin Krause; Deborah Johnston; Dmitri Debabov; Terry Wu; Lesley Farrington; Cassie Lane; Deborah L Higgins; Burt Christensen; J Kevin Judice; Koné Kaniga
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.

Authors:  Martin E Stryjewski; Vivian H Chu; William D O'Riordan; Brian L Warren; Lala M Dunbar; David M Young; Marc Vallée; Vance G Fowler; Joel Morganroth; Steven L Barriere; Michael M Kitt; G Ralph Corey
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.

Authors:  Anna King; Ian Phillips; Koné Kaniga
Journal:  J Antimicrob Chemother       Date:  2004-03-17       Impact factor: 5.790
  10 in total
  18 in total

1.  Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Heather C Elliott; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.

Authors:  Rodrigo E Mendes; Gary J Moet; Mike J Janechek; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

Review 3.  New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Authors:  George G Zhanel; Divna Calic; Frank Schweizer; Sheryl Zelenitsky; Heather Adam; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Alfred S Gin; Daryl J Hoban; James A Karlowsky
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 4.  Telavancin in the treatment of Staphylococcus aureus hospital-acquired and ventilator-associated pneumonia: clinical evidence and experience.

Authors:  Adamantia Liapikou; Katerina Dimakou; Michael Toumbis
Journal:  Ther Adv Respir Dis       Date:  2016-06-23       Impact factor: 4.031

5.  In vitro activity of telavancin against resistant gram-positive bacteria.

Authors:  Kevin M Krause; Marika Renelli; Stacey Difuntorum; Terry X Wu; Dmitri V Debabov; Bret M Benton
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

6.  Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.

Authors:  Deborah C Draghi; Bret M Benton; Kevin M Krause; Clyde Thornsberry; Chris Pillar; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2008-04-28       Impact factor: 5.191

Review 7.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

8.  Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits.

Authors:  Rabih O Darouiche; Mohammad D Mansouri; Marlowe J Schneidkraut
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

9.  In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.

Authors:  Sydney M Finegold; Mauricio Bolanos; Paula H Sumannen; Denise R Molitoris
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

10.  Stability of Reconstituted Telavancin Drug Product in Frozen Intravenous Bags.

Authors:  Zhengtian Gu; Anissa Wong; Elvira Raquinio; Alice Nguyen
Journal:  Hosp Pharm       Date:  2015-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.